Medplus Health Services' subsidiary, Optival Health Solutions, faced a three-day drug license suspension at a store by the Drugs Control Administration, impacting operations by ₹0.01 Crore.
Value
₹0.01 Cr
From
Drugs Control Administration, Haveri Circle, Karnataka
MedPlus Health Services' subsidiary, Optival Health Solutions, received a one-day drug license suspension from the Drugs Control Administration for a store in Telangana due to non-compliance.
Medplus Health Services' subsidiary, Optival Health, received a 7-day drug license suspension in Andhra Pradesh and stay orders for previous suspensions in Maharashtra.
Medplus Health Services disclosed that regulatory authorities suspended the drug licenses of five subsidiary stores for 3 to 7 days. The expected financial impact is ₹0.10 Crore.
Medplus Health Services reported a 7-day drug license suspension for a subsidiary store, impacting its operations with an estimated financial loss of ₹0.02 Crore.
Medplus Health Services' subsidiary, Optival Health Solutions, faced drug license suspensions for two stores from regulatory authorities, causing a total financial impact of Rs 0.0961 Crore.
Medplus Health Services reported a 5-day suspension of a drug license at a Mangalore store due to compliance issues. The expected financial impact is ₹0.03 Crore.
Medplus Health Services' subsidiary, Optival Health Solutions, faced a five-day drug license suspension at its Kapikad store due to regulatory violations. The impact is Rs 0.03 Crore.
MedPlus Health Services has filed board comments regarding a fine levied by the exchanges for non-compliance with Regulation 17(1A) of SEBI LODR Regulations, 2015.
Medplus approved acquiring the 0.01% residual stake in material subsidiary Optival Health Solutions for Rs.1.10 Crore. Optival's FY26 turnover of Rs.6,816 Crore will now be fully consolidated.
Medplus Health's subsidiary faces temporary drug license suspensions at two store locations in Bangalore and Pune, resulting in an estimated financial impact of Rs 0.15 Crore.
Alka Ajit Rangnekar, an immediate relative of a director, acquired 3,725 equity shares via off-market transfer. The transaction value amounts to approximately ₹0.24 Crore.
Medplus reported strong revenue growth but faced significant margin pressure from a lower private label mix and rising employee costs due to regulatory changes.
